Compare IDEXX Laboratories, Inc. (IDXX) vs ING Groep NV (ING) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs ING Groep NV — how do they compare? IDEXX Laboratories, Inc. trades at $519.54 (market cap $40.43B), while ING Groep NV trades at $33.31 (market cap $93.76B). The key difference: ING Groep NV is far larger — about 2.3× IDEXX Laboratories, Inc.'s market cap, and ING Groep NV pays a 3.95% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and ING Groep NV for 94 Days on average.
| IDXX | ING | |
|---|---|---|
Market Cap | $40.43B | $93.76B |
Volume | 692,164 | 4,620,220 |
Sector | Health | Financials |
52-Week High | $766.68 | $37.27 |
52-Week Low | $504.70 | $23.66 |
Typical Hold Time | 46 Days | 94 Days |
Enterprise Value | $41.32B | $236.48B |
Dividend Yield | — | 3.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
ING stock trades at $33.28, down 1.89% today, with bearish technical signals despite strong fundamentals. The company has beaten earnings estimates for three consecutive quarters, maintains a 28.34% net income margin, and analysts show strong support with 11 buy ratings versus no sell ratings. Recent news highlights management's raised ROE target above 16% for 2027 and strategic focus on organic growth.
The investment case balances solid profitability and analyst optimism against technical weakness and cash flow challenges. Upside potential exists from earnings momentum and strategic initiatives, while risks include persistent negative operating cash flows and regulatory scrutiny in international markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →
